Clinical effectiveness of apheresis in the treatment of progressive systemic sclerosis.
Scleroderma is a chronic disease of unknown origin characterized by diffuse sclerosis of the connective tissue of the integument and other organs. As in systemic lupus erythematosus (SLE), rheumatoid arthritis and dermatomyositis, a variety of antibodies may be found in the serum, suggesting that immune mechanisms may be involved. In two uremic patients with scleroderma, the effects were studied of the removal, by pheresis, of antinuclear antibodies, immune complexes, and immunoglobulin factors perpetuating the inflammatory response. We used a membrane plasmapheresis with a hollow-fiber type plasmafilter (Plasmaflo, Asahi) connected online with a hemofilter for conventional dialysis. The aim of this preliminary study was to induce a remission of the edematous inflammatory phase. The correlation of a improvement in clinical response and a decrease in the levels of immune complexes or other factors of inflammation was observed. In our view membrane-plasmapheresis is a process safely carried out by the hemodialysis staff and it may be of clinical effectiveness, especially, in patients with life-threatening complications of progressive systemic sclerosis.
D000328:Adult; D000906:Antibodies / Q000032:analysis; D000936:Antigen-Antibody Complex / Q000032:analysis; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D010951:Plasma Exchange; D012595:Scleroderma, Systemic / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000145:classification
D000906:Antibodies; D000936:Antigen-Antibody Complex; D007136:Immunoglobulins